05-172
Anti-IGF-I Antibody, clone Sm1.2
clone Sm1.2, Upstate®, from mouse
Sinónimos:
Mechano growth factor, insulin-like growth factor 1, insulin-like growth factor 1 (somatomedin C), somatomedin C
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
origen biológico
mouse
Nivel de calidad
forma del anticuerpo
purified immunoglobulin
clon
Sm1.2, monoclonal
reactividad de especies
avian, chicken, mouse, rat, human
fabricante / nombre comercial
Upstate®
técnicas
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
neutralization: suitable
western blot: suitable
isotipo
IgG1κ
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
dry ice
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... IGF1(3479)
Descripción general
Insulin-like growth factor 1 (IGF-1) is a polypeptide protein hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges.
IGF-1 is produced primarily by the liver as an endocrine hormone and targets tissues in a paracrine/autocrine fashion. Production is stimulated by growth hormone and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5b. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio. Its primary action is mediated by binding to specific IGF receptors present on many cell types in many tissues. The signal is transduced by intracellular events. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and multiplication and a potent inhibitor of programmed cell death.
IGF-1 is produced primarily by the liver as an endocrine hormone and targets tissues in a paracrine/autocrine fashion. Production is stimulated by growth hormone and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5b. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio. Its primary action is mediated by binding to specific IGF receptors present on many cell types in many tissues. The signal is transduced by intracellular events. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and multiplication and a potent inhibitor of programmed cell death.
Especificidad
IGF-I. (Russel, W.E., 1984). 40% cross reactivity to IGF-II. (van Wyk, J.J., 1997).
Possibly chicken. Occasional difficulty neutralizing rat IGF-I due to binding protein interference.
Inmunógeno
Human insulin-like growth factor I (IGF-I) purified from human plasma. (van Wyk, J.J., 1986).
Aplicación
Anti-IGF-I Antibody, clone Sm1.2 is an antibody against IGF-I for use in IH, IP, NEUT & WB.
Immunoprecipitation:
5 μg of a previous lot immunoprecipitated 100 ng of IGF-I.
Immunohistochemistry:
10 μg/mL of a previous lot was reported by an independent laboratory to detect IFG-I in formalin-fixed, paraffin-embedded skin sections.
(Lui, 1994).
Neutralization:
10-20 μg/mL of a previous lot inhibited the activity of 10 ng/mL of IGF-I as determined by testing with chicken embryo fibroblasts (CEF) using an ATP endpoint assay (ATPLiteTM-M, Packard Instruments).
5 μg of a previous lot immunoprecipitated 100 ng of IGF-I.
Immunohistochemistry:
10 μg/mL of a previous lot was reported by an independent laboratory to detect IFG-I in formalin-fixed, paraffin-embedded skin sections.
(Lui, 1994).
Neutralization:
10-20 μg/mL of a previous lot inhibited the activity of 10 ng/mL of IGF-I as determined by testing with chicken embryo fibroblasts (CEF) using an ATP endpoint assay (ATPLiteTM-M, Packard Instruments).
Research Category
Signaling
Signaling
Research Sub Category
Insulin/Energy Signaling
Insulin/Energy Signaling
Calidad
Evaluated on IGF-I (Catalog # 01-208) under non-reducing conditions.
Western Blot Analysis:
0.5-2 μg/mL of this antibody detected 100 ng of IGF-I (Catalog # 01-208) under non-reducing conditions.
Western Blot Analysis:
0.5-2 μg/mL of this antibody detected 100 ng of IGF-I (Catalog # 01-208) under non-reducing conditions.
Descripción de destino
17 kDa, migrates to ~7 kDa
Forma física
Format: Purified
Protein G Purified
Purified mouse IgG1κ lyophilized powder, lyophilized from 105 μL of 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.1 mM EDTA.
Almacenamiento y estabilidad
Stable for 1 year at -20ºC from date of receipt.
Nota de análisis
Control
MCF-7 cell extracts
MCF-7 cell extracts
Otras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Información legal
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 1
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Peter Zahradka et al.
Endocrinology, 145(6), 2978-2987 (2004-02-21)
Angiotensin II (AngII) activates phosphatidylinositol 3-kinase (PI3-kinase), a known effector of receptor tyrosine kinases. Treatment of smooth muscle cells with AngII has also been shown to promote phosphorylation of various tyrosine kinase receptors. We therefore investigated the relationship between AngII
Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C.
Russell, W E, et al.
Proceedings of the National Academy of Sciences of the USA, 81, 2389-2392 (1984)
PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: the PTH-IGF-I axis.
Green, J; Goldberg, R; Maor, G
Kidney International null
G Hudelist et al.
Endocrine-related cancer, 14(4), 1053-1062 (2007-11-30)
BRCA1/2 mutations predispose to early onset breast and ovarian cancers. The phenotypic expression of mutant alleles, however, is thought to be modified by factors that are also involved in the pathogenesis of sporadic breast cancer. One such protein is IGF-I
Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer.
Y Z Wang, Y C Wong
Prostate null
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico